Loading rounds…
Loading rounds…
Explore funding rounds, the companies behind them and the investors taking part.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| TT TRIMTECH TherapeuticsCompany profile Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases | $47M | Seed+Seed | Biotech | United Kingdom | Investors |
Ranked by rounds participated in · All time
AusperBio, Abcuro, Infinimmune
Epicrispr Biotechnologies, Draig Therapeutics, Triveni Bio
LifeMine Therapeutics, Ollin Biosciences, SonoThera
Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics
Leal Therapeutics, Amplifica Holdings Group, InduPro
Explore published rounds while the next edition is being prepared.
| NB NorthLinks BioCompany profile Develops broad-spectrum antiviral prophylactic therapies for respiratory infections Develops broad-spectrum antiviral prophylactic therapies for respiratory infections | $34M | Undisclosed | Biotech | United States | Investors |
| OB Osanni BioCompany profile Platform that discovers and de-risks novel drug programs in ophthalmology and cardiology via affiliate company model Platform that discovers and de-risks novel drug programs in ophthalmology and cardiology via affiliate company model | $190M | Series B | Biotech | United States | Investors |
| K KyrokCompany profile Builds an AI operating system for supply chain management in pharma and chemical SMEs across Europe Builds an AI operating system for supply chain management in pharma and chemical SMEs across Europe | €3.1M | Pre-SeedPre-seed | Biotech | Germany | Investors |
| BP Bionyra PharmaCompany profile Developing next-generation biologics for severe immunological and inflammatory diseases Developing next-generation biologics for severe immunological and inflammatory diseases | $165M | Series A | Biotech | France | Investors |
| D DropGenieCompany profile Miniaturizes gene editing workflows to enable direct edits on primary patient cells for cell therapy and drug discovery Miniaturizes gene editing workflows to enable direct edits on primary patient cells for cell therapy and drug discovery | Undisclosed | Seed+Seed | Biotech | Canada | Investors |
| H HistoSonicsCompany profile Develops non-invasive histotripsy platform using focused ultrasound to mechanically destroy tumors without surgery Develops non-invasive histotripsy platform using focused ultrasound to mechanically destroy tumors without surgery | Undisclosed | StrategicUndisclosed | Biotech, Healthtech | United States | Investors |
| LT Lys TherapeuticsCompany profile Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke | >€25M | Seed | Biotech | France | Investors |
| GT Graph TherapeuticsCompany profile Develops precision medicines for inflammatory and immune-mediated diseases using AI-powered patient cell analysis Develops precision medicines for inflammatory and immune-mediated diseases using AI-powered patient cell analysis | $5M | Series A | Biotech | Austria | Investors |
| CB ChemT BiotechnologyCompany profile Develops AI virtual cell platform to optimize biomanufacturing processes for biopharma companies Develops AI virtual cell platform to optimize biomanufacturing processes for biopharma companies | $4M | Seed | Biotech | Singapore | Investors |